Jordern5665的个人主页 - 老虎社区

Jordern5665

Jordern5665

暂无个人介绍

IP属地：未知

8关注

1粉丝

0主题

0勋章

2021-07-01

Thanks

2021-06-24

Nice

The red hot housing market is slowing down the economy: Morning Brief

2021-06-24

Nice

A 6.7-Inch iPhone At $900? Analyst Says Apple Will Bring This Product To Market Next Year

2021-06-24

Apple is the best

2021-06-21

Can invest this one ?

Orphazyme rose more than 6% in premarket trading

2021-06-12

[Cry]

抱歉，原内容已删除

2021-06-11

[Cool]

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3586338829912658","uuid":"3586338829912658","gmtCreate":1623247508144,"gmtModify":1623377522326,"name":"Jordern5665","pinyin":"jordern5665","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/a1392e698d9d8446e6f5ac612e339304","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":8,"tweetSize":7,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.51%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.54%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":151241265,"gmtCreate":1625096396357,"gmtModify":1631891683958,"author":{"id":"3586338829912658","authorId":"3586338829912658","name":"Jordern5665","avatar":"https://static.tigerbbs.com/a1392e698d9d8446e6f5ac612e339304","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586338829912658","authorIdStr":"3586338829912658"},"themes":[],"htmlText":"Thanks&nbsp;","listText":"Thanks&nbsp;","text":"Thanks","images":[{"img":"https://static.tigerbbs.com/d1cbb1a770832b5037394f9ae1894e5d","width":"750","height":"1238"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/151241265","isVote":1,"tweetType":1,"viewCount":1317,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":128455071,"gmtCreate":1624528879993,"gmtModify":1631891683966,"author":{"id":"3586338829912658","authorId":"3586338829912658","name":"Jordern5665","avatar":"https://static.tigerbbs.com/a1392e698d9d8446e6f5ac612e339304","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586338829912658","authorIdStr":"3586338829912658"},"themes":[],"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128455071","repostId":"2145043969","repostType":4,"repost":{"id":"2145043969","kind":"news","pubTimestamp":1624525868,"share":"https://ttm.financial/m/news/2145043969?lang=&edition=full","pubTime":"2021-06-24 17:11","market":"us","language":"en","title":"The red hot housing market is slowing down the economy: Morning Brief","url":"https://stock-news.laohu8.com/highlight/detail?id=2145043969","media":"Yahoo Finance","summary":"Supply can't meet demand, housing edition\nWe've periodically checked in on the housing market at The","content":"<p><img src=\"https://static.tigerbbs.com/a66604c7e5fcdb480747b6a4be692a3d\" tg-width=\"3504\" tg-height=\"2336\" referrerpolicy=\"no-referrer\"></p>\n<h3>Supply can't meet demand, housing edition</h3>\n<p>We've periodically checked in on the housing market at The Morning Brief over the last year, and the story has, in general, been consistent.</p>\n<p>Home prices are rising amid a surge in demand, while low interest rates enable buyers to afford more house.</p>\n<p>But cracks in the housing market have been starting to show, and now are likely to dent U.S gross domestic product (GDP) in the current quarter.</p>\n<p>The hot housing market, in other words, has actually become a drag on growth.</p>\n<p>Housing economist Bill McBride noted Wednesday that the economics group at Goldman Sachs cut its forecast for current quarter GDP, to an annualized growth rate of 8.75%, from a previous outlook for growth to hit 9%. A small change, to be sure. But an example of how the economy-wide demand glut does have some natural speed brakes.</p>\n<p>On Wednesday, May's report on new home sales showed the pace of sales fell 5.9% last month to an annualized rate of 769,000. The actual number of homes sold last month was the lowest in a year. This report followed Tuesday's gauge on existing home sales, which declined for the fourth straight month to an annualized rate of 5.8 million homes.</p>\n<p>These drops in the pace of sales, however, were accompanied by a continued surge in pricing as demand cannot be met. The median increase in the price of an existing home sold rose 23.6% over last year in May, while the median increase in a new home's price was 18.1% over last year. But this increase in prices can't offset the negative growth impact of fewer homes trading hands.</p>\n<p>Mahir Rasheed, U.S. economist at Oxford Economics, flagged in a note Wednesday that while home sales are likely to be flat or lower for the rest of the year, backlogs should keep homebuilder activity supported.</p>\n<p>\"Nearly 90% of the for-sale inventory in May was of homes where construction is ongoing or has not started, while 36% of homes already sold have not yet broken ground,\" Rasheed wrote.</p>\n<p>\"These backlogs should support homebuilder activity even if the current pace of home sales moderates, although there are likely to be delays in the near term as builders contend with supply chain issues,\" he added. Rasheed also noted that with lumber prices coming down, builder cost pressures being pushed to buyers could ease.</p>\n<p>But in a note to clients published Wednesday, Ian Shepherdson at Pantheon Macroeconomics was less sanguine on the situation. \"</p>\n<p>New home sales \"look set to fall further, with a decent chance they’ll soon be back below the pre-COVID trend,\" Shepherdson wrote. \"The story here, we think, is simply that demand in the suburbs has fallen as COVID fear has faded. Inventory remains low but it is rising rapidly; supply hit 5.1 months of current sales in May, up from 3.6 months in January.\"</p>\n<p>Shepherdson added that this data points to \"an accident waiting to happen.\"</p>\n<p>We argued earlier this month that lumber prices cratering reveal to us the future of this recovery. A future in which the most acute pricing pressures ease just as they fell: abruptly.</p>\n<p>But abrupt turns in the economy don't create healthy conditions. Rather, these turns set the table for investors who couldn't be bullish enough coming into 2021 to suddenly find themselves caught offside the other way.</p>\n<p><i>By Myles Udland, reporter and anchor for Yahoo Finance Live. Follow him at @MylesUdland</i></p>\n<h3><b>What to watch today</b></h3>\n<p><b>Economy </b></p>\n<ul>\n <li>8:30 a.m. ET:<b> Advance Goods Trade Balance, </b>May (-$87.5 billion expected, -$85.2 billion in April)</li>\n <li>8:30 a.m. ET: <b>Wholesale inventories,</b> May preliminary (0.8% in April)</li>\n <li>8:30 a.m. ET: <b>Durable goods orders, </b>May preliminary (2.8% expected, -1.3% in April)</li>\n <li>8:30 a.m. ET: <b>Durable goods orders excluding transportation, </b>May preliminary (0.7% expected, 1.0% in April)</li>\n <li>8:30 a.m. ET: <b>Non-defense capital goods orders excluding aircraft, </b>May preliminary (0.6% expected, 2.2% in April)</li>\n <li>8:30 a.m. ET: <b>Non-defense capital goods shipments excluding aircraft</b> (0.8% expected, 0.9% in April)</li>\n <li>8:30 a.m. ET: <b>GDP annualized, </b>quarter-over-quarter, Q1 third print (6.4% expected, 6.4% in prior print)</li>\n <li>8:30 a.m. ET: <b>Personal consumption,</b> Q1 third print (11.4% expected, 11.3% in prior print)</li>\n <li>8:30 a.m. ET: <b>GDP Price Index,</b> Q1 third print (4.3% expected, 4.3% in prior print)</li>\n <li>8:30 a.m. ET:<b>&nbsp;Initial jobless claims, </b>week ended June 19 (380,000 expected, 412,000 in prior print)</li>\n <li>8:30 a.m. ET: <b>Continuing claims, </b>week ended June 12 (3.460 million expected, 3.518 million in prior print)</li>\n <li>11:00 a.m. ET: <b>Kansas City Fed Manufacturing Activity Index,</b> June (24 expected, 26 in prior print)</li>\n</ul>\n<p><b>Earnings</b></p>\n<p><b>Pre-market</b></p>\n<ul>\n <li>7:00 a.m. ET: <b>Darden Restaurants (DRI)</b> is expected to report adjusted earnings of $1.77 per share on revenue of $2.19 billion</li>\n</ul>\n<p><b>Post-market</b></p>\n<ul>\n <li>4:00 p.m. ET:<b> Fedex (FDX) </b>is expected to report adjusted earnings of $5.00 per share on revenue of $21.49 billion</li>\n <li>4:15 p.m. ET: <b>Nike (NKE)</b> is expected to report adjusted earnings of 50 cents per share on revenue of $11.03 billion</li>\n</ul>\n<h3><b>Top News</b></h3>\n<p><b>&nbsp;</b>U.S. software mogul John McAfee dies by hanging in Spanish prison, lawyer says [Reuters]</p>\n<p>Bitcoin trading above $32,000 but cryptos remain under pressure {Yahoo Finance UK]</p>\n<p>Senators to pitch bipartisan infrastructure plan to Biden [AP]</p>\n<p>Microsoft’s big Windows 11 event is coming up — here's what to expect [Yahoo Finance]</p>\n<h3><b>Yahoo Finance Highlights</b></h3>\n<p>Fed cautious about return to pre-pandemic labor market</p>\n<p>Activist investor who shook up Bed Bath &amp; Beyond and Kohl's says this is the next big retail opportunity</p>\n<p>GDP is back. Workers are not</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The red hot housing market is slowing down the economy: Morning Brief</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe red hot housing market is slowing down the economy: Morning Brief\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 17:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/the-red-hot-housing-market-is-slowing-down-the-economy-morning-brief-091108953.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Supply can't meet demand, housing edition\nWe've periodically checked in on the housing market at The Morning Brief over the last year, and the story has, in general, been consistent.\nHome prices are ...</p>\n\n<a href=\"https://finance.yahoo.com/news/the-red-hot-housing-market-is-slowing-down-the-economy-morning-brief-091108953.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/3a27d956c99f35da42b4f75734adb724","relate_stocks":{".SPX":"S&P 500 Index",".DJI":"道琼斯","LEN":"莱纳建筑公司","PHM":"普得集团","SPY":"标普500ETF","XHB":"房屋建筑商指数ETF-SPDR","DHI":"霍顿房屋",".IXIC":"NASDAQ Composite","TOL":"托尔兄弟","KBH":"KB Home"},"source_url":"https://finance.yahoo.com/news/the-red-hot-housing-market-is-slowing-down-the-economy-morning-brief-091108953.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2145043969","content_text":"Supply can't meet demand, housing edition\nWe've periodically checked in on the housing market at The Morning Brief over the last year, and the story has, in general, been consistent.\nHome prices are rising amid a surge in demand, while low interest rates enable buyers to afford more house.\nBut cracks in the housing market have been starting to show, and now are likely to dent U.S gross domestic product (GDP) in the current quarter.\nThe hot housing market, in other words, has actually become a drag on growth.\nHousing economist Bill McBride noted Wednesday that the economics group at Goldman Sachs cut its forecast for current quarter GDP, to an annualized growth rate of 8.75%, from a previous outlook for growth to hit 9%. A small change, to be sure. But an example of how the economy-wide demand glut does have some natural speed brakes.\nOn Wednesday, May's report on new home sales showed the pace of sales fell 5.9% last month to an annualized rate of 769,000. The actual number of homes sold last month was the lowest in a year. This report followed Tuesday's gauge on existing home sales, which declined for the fourth straight month to an annualized rate of 5.8 million homes.\nThese drops in the pace of sales, however, were accompanied by a continued surge in pricing as demand cannot be met. The median increase in the price of an existing home sold rose 23.6% over last year in May, while the median increase in a new home's price was 18.1% over last year. But this increase in prices can't offset the negative growth impact of fewer homes trading hands.\nMahir Rasheed, U.S. economist at Oxford Economics, flagged in a note Wednesday that while home sales are likely to be flat or lower for the rest of the year, backlogs should keep homebuilder activity supported.\n\"Nearly 90% of the for-sale inventory in May was of homes where construction is ongoing or has not started, while 36% of homes already sold have not yet broken ground,\" Rasheed wrote.\n\"These backlogs should support homebuilder activity even if the current pace of home sales moderates, although there are likely to be delays in the near term as builders contend with supply chain issues,\" he added. Rasheed also noted that with lumber prices coming down, builder cost pressures being pushed to buyers could ease.\nBut in a note to clients published Wednesday, Ian Shepherdson at Pantheon Macroeconomics was less sanguine on the situation. \"\nNew home sales \"look set to fall further, with a decent chance they’ll soon be back below the pre-COVID trend,\" Shepherdson wrote. \"The story here, we think, is simply that demand in the suburbs has fallen as COVID fear has faded. Inventory remains low but it is rising rapidly; supply hit 5.1 months of current sales in May, up from 3.6 months in January.\"\nShepherdson added that this data points to \"an accident waiting to happen.\"\nWe argued earlier this month that lumber prices cratering reveal to us the future of this recovery. A future in which the most acute pricing pressures ease just as they fell: abruptly.\nBut abrupt turns in the economy don't create healthy conditions. Rather, these turns set the table for investors who couldn't be bullish enough coming into 2021 to suddenly find themselves caught offside the other way.\nBy Myles Udland, reporter and anchor for Yahoo Finance Live. Follow him at @MylesUdland\nWhat to watch today\nEconomy \n\n8:30 a.m. ET: Advance Goods Trade Balance, May (-$87.5 billion expected, -$85.2 billion in April)\n8:30 a.m. ET: Wholesale inventories, May preliminary (0.8% in April)\n8:30 a.m. ET: Durable goods orders, May preliminary (2.8% expected, -1.3% in April)\n8:30 a.m. ET: Durable goods orders excluding transportation, May preliminary (0.7% expected, 1.0% in April)\n8:30 a.m. ET: Non-defense capital goods orders excluding aircraft, May preliminary (0.6% expected, 2.2% in April)\n8:30 a.m. ET: Non-defense capital goods shipments excluding aircraft (0.8% expected, 0.9% in April)\n8:30 a.m. ET: GDP annualized, quarter-over-quarter, Q1 third print (6.4% expected, 6.4% in prior print)\n8:30 a.m. ET: Personal consumption, Q1 third print (11.4% expected, 11.3% in prior print)\n8:30 a.m. ET: GDP Price Index, Q1 third print (4.3% expected, 4.3% in prior print)\n8:30 a.m. ET: Initial jobless claims, week ended June 19 (380,000 expected, 412,000 in prior print)\n8:30 a.m. ET: Continuing claims, week ended June 12 (3.460 million expected, 3.518 million in prior print)\n11:00 a.m. ET: Kansas City Fed Manufacturing Activity Index, June (24 expected, 26 in prior print)\n\nEarnings\nPre-market\n\n7:00 a.m. ET: Darden Restaurants (DRI) is expected to report adjusted earnings of $1.77 per share on revenue of $2.19 billion\n\nPost-market\n\n4:00 p.m. ET: Fedex (FDX) is expected to report adjusted earnings of $5.00 per share on revenue of $21.49 billion\n4:15 p.m. ET: Nike (NKE) is expected to report adjusted earnings of 50 cents per share on revenue of $11.03 billion\n\nTop News\n U.S. software mogul John McAfee dies by hanging in Spanish prison, lawyer says [Reuters]\nBitcoin trading above $32,000 but cryptos remain under pressure {Yahoo Finance UK]\nSenators to pitch bipartisan infrastructure plan to Biden [AP]\nMicrosoft’s big Windows 11 event is coming up — here's what to expect [Yahoo Finance]\nYahoo Finance Highlights\nFed cautious about return to pre-pandemic labor market\nActivist investor who shook up Bed Bath & Beyond and Kohl's says this is the next big retail opportunity\nGDP is back. Workers are not","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9,"DHI":0.6,"KBH":0.9,"LEN":0.6,"PHM":0.6,"SPY":0.9,"TOL":0.6,"XHB":0.9}},"isVote":1,"tweetType":1,"viewCount":1321,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128456269,"gmtCreate":1624528839051,"gmtModify":1631891683978,"author":{"id":"3586338829912658","authorId":"3586338829912658","name":"Jordern5665","avatar":"https://static.tigerbbs.com/a1392e698d9d8446e6f5ac612e339304","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586338829912658","authorIdStr":"3586338829912658"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128456269","repostId":"1184361611","repostType":4,"repost":{"id":"1184361611","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1624526066,"share":"https://ttm.financial/m/news/1184361611?lang=&edition=full","pubTime":"2021-06-24 17:14","market":"us","language":"en","title":"A 6.7-Inch iPhone At $900? Analyst Says Apple Will Bring This Product To Market Next Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1184361611","media":"Benzinga","summary":"Apple Inc(NASDAQ:AAPL) will launch two lower-end iPhones with larger screens next year, as per analy","content":"<p><b>Apple Inc</b>(NASDAQ:AAPL) will launch two lower-end iPhones with larger screens next year, as per analyst Ming-Chi Kuo.</p>\n<p><b>What Happened:</b>&nbsp;Apple’s lineup in the second half of 2022 will include two iPhone lines with 6.7-inch screens — one will&nbsp;serve the low-end market and another will cater to the premium one, Kuo said, as per9to5Mac.&nbsp;Both these models will also be available in the 6.1-inch screen size.</p>\n<p>According to the report, Kuo believes the 2022 lineup will have under-display fingerprint support and it will be available at the most affordable price point for a large screen and expected to be under $900.</p>\n<p>The current iPhone lineup includes the 6.7-inch iPhone 12 Pro Max, which is priced at $1,099. Kuo said the 2022 lineup could be named iPhone 14, iPhone 14 Pro, and iPhone 14 Pro Max.</p>\n<p><b>Why It Matters:</b>&nbsp;Apple’s iPhone 12 Pro Max, launched last year, is its biggest phone to-date. The company’s yet-to-be-announced 2021 lineup is expected to sport the same variants as its predecessor from last year and the big changes will only be revealed next year, as per reports.</p>\n<p><b>Price Action:</b>&nbsp;Apple shares closed 0.2% lower at $133.70 on Wednesday.</p>\n<p><img src=\"https://static.tigerbbs.com/e12ede45502bee1f416acaa08de1af92\" tg-width=\"661\" tg-height=\"250\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A 6.7-Inch iPhone At $900? Analyst Says Apple Will Bring This Product To Market Next Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA 6.7-Inch iPhone At $900? Analyst Says Apple Will Bring This Product To Market Next Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-06-24 17:14</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Apple Inc</b>(NASDAQ:AAPL) will launch two lower-end iPhones with larger screens next year, as per analyst Ming-Chi Kuo.</p>\n<p><b>What Happened:</b>&nbsp;Apple’s lineup in the second half of 2022 will include two iPhone lines with 6.7-inch screens — one will&nbsp;serve the low-end market and another will cater to the premium one, Kuo said, as per9to5Mac.&nbsp;Both these models will also be available in the 6.1-inch screen size.</p>\n<p>According to the report, Kuo believes the 2022 lineup will have under-display fingerprint support and it will be available at the most affordable price point for a large screen and expected to be under $900.</p>\n<p>The current iPhone lineup includes the 6.7-inch iPhone 12 Pro Max, which is priced at $1,099. Kuo said the 2022 lineup could be named iPhone 14, iPhone 14 Pro, and iPhone 14 Pro Max.</p>\n<p><b>Why It Matters:</b>&nbsp;Apple’s iPhone 12 Pro Max, launched last year, is its biggest phone to-date. The company’s yet-to-be-announced 2021 lineup is expected to sport the same variants as its predecessor from last year and the big changes will only be revealed next year, as per reports.</p>\n<p><b>Price Action:</b>&nbsp;Apple shares closed 0.2% lower at $133.70 on Wednesday.</p>\n<p><img src=\"https://static.tigerbbs.com/e12ede45502bee1f416acaa08de1af92\" tg-width=\"661\" tg-height=\"250\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1184361611","content_text":"Apple Inc(NASDAQ:AAPL) will launch two lower-end iPhones with larger screens next year, as per analyst Ming-Chi Kuo.\nWhat Happened: Apple’s lineup in the second half of 2022 will include two iPhone lines with 6.7-inch screens — one will serve the low-end market and another will cater to the premium one, Kuo said, as per9to5Mac. Both these models will also be available in the 6.1-inch screen size.\nAccording to the report, Kuo believes the 2022 lineup will have under-display fingerprint support and it will be available at the most affordable price point for a large screen and expected to be under $900.\nThe current iPhone lineup includes the 6.7-inch iPhone 12 Pro Max, which is priced at $1,099. Kuo said the 2022 lineup could be named iPhone 14, iPhone 14 Pro, and iPhone 14 Pro Max.\nWhy It Matters: Apple’s iPhone 12 Pro Max, launched last year, is its biggest phone to-date. The company’s yet-to-be-announced 2021 lineup is expected to sport the same variants as its predecessor from last year and the big changes will only be revealed next year, as per reports.\nPrice Action: Apple shares closed 0.2% lower at $133.70 on Wednesday.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":879,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128456309,"gmtCreate":1624528813301,"gmtModify":1631891683991,"author":{"id":"3586338829912658","authorId":"3586338829912658","name":"Jordern5665","avatar":"https://static.tigerbbs.com/a1392e698d9d8446e6f5ac612e339304","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586338829912658","authorIdStr":"3586338829912658"},"themes":[],"htmlText":"Apple is the best","listText":"Apple is the best","text":"Apple is the best","images":[{"img":"https://static.tigerbbs.com/036a9e33758775221b0e8c4dc3ad81d8","width":"1125","height":"3231"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128456309","isVote":1,"tweetType":1,"viewCount":1609,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":167545445,"gmtCreate":1624279592087,"gmtModify":1631883985922,"author":{"id":"3586338829912658","authorId":"3586338829912658","name":"Jordern5665","avatar":"https://static.tigerbbs.com/a1392e698d9d8446e6f5ac612e339304","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586338829912658","authorIdStr":"3586338829912658"},"themes":[],"htmlText":"Can invest this one ?","listText":"Can invest this one ?","text":"Can invest this one ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/167545445","repostId":"1184501396","repostType":2,"repost":{"id":"1184501396","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624267024,"share":"https://ttm.financial/m/news/1184501396?lang=&edition=full","pubTime":"2021-06-21 17:17","market":"us","language":"en","title":"Orphazyme rose more than 6% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1184501396","media":"Tiger Newspress","summary":"(June 21) Orphazyme rose more than 6% in premarket trading. \n\nWhat happened\nShares of Orphazyme, a c","content":"<p>(June 21)&nbsp;Orphazyme rose more than 6% in premarket trading.&nbsp;</p>\n<p><img src=\"https://static.tigerbbs.com/a1e2eb27cc68ce74ddd21a64a64634cf\" tg-width=\"719\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Orphazyme</b>, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last&nbsp;Friday.</p>\n<p><b>So what</b></p>\n<p>The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.</p>\n<p>Instead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.</p>\n<p>Many institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.</p>\n<p><b>Now what</b></p>\n<p>According to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.</p>\n<p>Some shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.</p>\n<p>Despite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.</p>\n<p></p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme rose more than 6% in premarket trading </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme rose more than 6% in premarket trading \n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-21 17:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(June 21)&nbsp;Orphazyme rose more than 6% in premarket trading.&nbsp;</p>\n<p><img src=\"https://static.tigerbbs.com/a1e2eb27cc68ce74ddd21a64a64634cf\" tg-width=\"719\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Orphazyme</b>, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last&nbsp;Friday.</p>\n<p><b>So what</b></p>\n<p>The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.</p>\n<p>Instead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.</p>\n<p>Many institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.</p>\n<p><b>Now what</b></p>\n<p>According to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.</p>\n<p>Some shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.</p>\n<p>Despite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.</p>\n<p></p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1184501396","content_text":"(June 21) Orphazyme rose more than 6% in premarket trading. \n\nWhat happened\nShares of Orphazyme, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last Friday.\nSo what\nThe FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.\nInstead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.\nMany institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.\nNow what\nAccording to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.\nSome shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.\nDespite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"tweetType":1,"viewCount":561,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":188515238,"gmtCreate":1623454701824,"gmtModify":1631891684004,"author":{"id":"3586338829912658","authorId":"3586338829912658","name":"Jordern5665","avatar":"https://static.tigerbbs.com/a1392e698d9d8446e6f5ac612e339304","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586338829912658","authorIdStr":"3586338829912658"},"themes":[],"htmlText":"[Cry]&nbsp;","listText":"[Cry]&nbsp;","text":"[Cry]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/188515238","repostId":"2142858202","repostType":4,"isVote":1,"tweetType":1,"viewCount":786,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":183450283,"gmtCreate":1623343136942,"gmtModify":1631891684017,"author":{"id":"3586338829912658","authorId":"3586338829912658","name":"Jordern5665","avatar":"https://static.tigerbbs.com/a1392e698d9d8446e6f5ac612e339304","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586338829912658","authorIdStr":"3586338829912658"},"themes":[],"htmlText":"[Cool]&nbsp;","listText":"[Cool]&nbsp;","text":"[Cool]","images":[{"img":"https://static.tigerbbs.com/5ea4062b862709c77427ce72a351be07","width":"1125","height":"3199"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/183450283","isVote":1,"tweetType":1,"viewCount":1014,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":128456269,"gmtCreate":1624528839051,"gmtModify":1631891683978,"author":{"id":"3586338829912658","authorId":"3586338829912658","name":"Jordern5665","avatar":"https://static.tigerbbs.com/a1392e698d9d8446e6f5ac612e339304","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586338829912658","authorIdStr":"3586338829912658"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128456269","repostId":"1184361611","repostType":4,"repost":{"id":"1184361611","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1624526066,"share":"https://ttm.financial/m/news/1184361611?lang=&edition=full","pubTime":"2021-06-24 17:14","market":"us","language":"en","title":"A 6.7-Inch iPhone At $900? Analyst Says Apple Will Bring This Product To Market Next Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1184361611","media":"Benzinga","summary":"Apple Inc(NASDAQ:AAPL) will launch two lower-end iPhones with larger screens next year, as per analy","content":"<p><b>Apple Inc</b>(NASDAQ:AAPL) will launch two lower-end iPhones with larger screens next year, as per analyst Ming-Chi Kuo.</p>\n<p><b>What Happened:</b>&nbsp;Apple’s lineup in the second half of 2022 will include two iPhone lines with 6.7-inch screens — one will&nbsp;serve the low-end market and another will cater to the premium one, Kuo said, as per9to5Mac.&nbsp;Both these models will also be available in the 6.1-inch screen size.</p>\n<p>According to the report, Kuo believes the 2022 lineup will have under-display fingerprint support and it will be available at the most affordable price point for a large screen and expected to be under $900.</p>\n<p>The current iPhone lineup includes the 6.7-inch iPhone 12 Pro Max, which is priced at $1,099. Kuo said the 2022 lineup could be named iPhone 14, iPhone 14 Pro, and iPhone 14 Pro Max.</p>\n<p><b>Why It Matters:</b>&nbsp;Apple’s iPhone 12 Pro Max, launched last year, is its biggest phone to-date. The company’s yet-to-be-announced 2021 lineup is expected to sport the same variants as its predecessor from last year and the big changes will only be revealed next year, as per reports.</p>\n<p><b>Price Action:</b>&nbsp;Apple shares closed 0.2% lower at $133.70 on Wednesday.</p>\n<p><img src=\"https://static.tigerbbs.com/e12ede45502bee1f416acaa08de1af92\" tg-width=\"661\" tg-height=\"250\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A 6.7-Inch iPhone At $900? Analyst Says Apple Will Bring This Product To Market Next Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA 6.7-Inch iPhone At $900? Analyst Says Apple Will Bring This Product To Market Next Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-06-24 17:14</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Apple Inc</b>(NASDAQ:AAPL) will launch two lower-end iPhones with larger screens next year, as per analyst Ming-Chi Kuo.</p>\n<p><b>What Happened:</b>&nbsp;Apple’s lineup in the second half of 2022 will include two iPhone lines with 6.7-inch screens — one will&nbsp;serve the low-end market and another will cater to the premium one, Kuo said, as per9to5Mac.&nbsp;Both these models will also be available in the 6.1-inch screen size.</p>\n<p>According to the report, Kuo believes the 2022 lineup will have under-display fingerprint support and it will be available at the most affordable price point for a large screen and expected to be under $900.</p>\n<p>The current iPhone lineup includes the 6.7-inch iPhone 12 Pro Max, which is priced at $1,099. Kuo said the 2022 lineup could be named iPhone 14, iPhone 14 Pro, and iPhone 14 Pro Max.</p>\n<p><b>Why It Matters:</b>&nbsp;Apple’s iPhone 12 Pro Max, launched last year, is its biggest phone to-date. The company’s yet-to-be-announced 2021 lineup is expected to sport the same variants as its predecessor from last year and the big changes will only be revealed next year, as per reports.</p>\n<p><b>Price Action:</b>&nbsp;Apple shares closed 0.2% lower at $133.70 on Wednesday.</p>\n<p><img src=\"https://static.tigerbbs.com/e12ede45502bee1f416acaa08de1af92\" tg-width=\"661\" tg-height=\"250\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1184361611","content_text":"Apple Inc(NASDAQ:AAPL) will launch two lower-end iPhones with larger screens next year, as per analyst Ming-Chi Kuo.\nWhat Happened: Apple’s lineup in the second half of 2022 will include two iPhone lines with 6.7-inch screens — one will serve the low-end market and another will cater to the premium one, Kuo said, as per9to5Mac. Both these models will also be available in the 6.1-inch screen size.\nAccording to the report, Kuo believes the 2022 lineup will have under-display fingerprint support and it will be available at the most affordable price point for a large screen and expected to be under $900.\nThe current iPhone lineup includes the 6.7-inch iPhone 12 Pro Max, which is priced at $1,099. Kuo said the 2022 lineup could be named iPhone 14, iPhone 14 Pro, and iPhone 14 Pro Max.\nWhy It Matters: Apple’s iPhone 12 Pro Max, launched last year, is its biggest phone to-date. The company’s yet-to-be-announced 2021 lineup is expected to sport the same variants as its predecessor from last year and the big changes will only be revealed next year, as per reports.\nPrice Action: Apple shares closed 0.2% lower at $133.70 on Wednesday.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":879,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128456309,"gmtCreate":1624528813301,"gmtModify":1631891683991,"author":{"id":"3586338829912658","authorId":"3586338829912658","name":"Jordern5665","avatar":"https://static.tigerbbs.com/a1392e698d9d8446e6f5ac612e339304","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586338829912658","authorIdStr":"3586338829912658"},"themes":[],"htmlText":"Apple is the best","listText":"Apple is the best","text":"Apple is the best","images":[{"img":"https://static.tigerbbs.com/036a9e33758775221b0e8c4dc3ad81d8","width":"1125","height":"3231"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128456309","isVote":1,"tweetType":1,"viewCount":1609,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":167545445,"gmtCreate":1624279592087,"gmtModify":1631883985922,"author":{"id":"3586338829912658","authorId":"3586338829912658","name":"Jordern5665","avatar":"https://static.tigerbbs.com/a1392e698d9d8446e6f5ac612e339304","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586338829912658","authorIdStr":"3586338829912658"},"themes":[],"htmlText":"Can invest this one ?","listText":"Can invest this one ?","text":"Can invest this one ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/167545445","repostId":"1184501396","repostType":2,"repost":{"id":"1184501396","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624267024,"share":"https://ttm.financial/m/news/1184501396?lang=&edition=full","pubTime":"2021-06-21 17:17","market":"us","language":"en","title":"Orphazyme rose more than 6% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1184501396","media":"Tiger Newspress","summary":"(June 21) Orphazyme rose more than 6% in premarket trading. \n\nWhat happened\nShares of Orphazyme, a c","content":"<p>(June 21)&nbsp;Orphazyme rose more than 6% in premarket trading.&nbsp;</p>\n<p><img src=\"https://static.tigerbbs.com/a1e2eb27cc68ce74ddd21a64a64634cf\" tg-width=\"719\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Orphazyme</b>, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last&nbsp;Friday.</p>\n<p><b>So what</b></p>\n<p>The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.</p>\n<p>Instead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.</p>\n<p>Many institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.</p>\n<p><b>Now what</b></p>\n<p>According to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.</p>\n<p>Some shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.</p>\n<p>Despite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.</p>\n<p></p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme rose more than 6% in premarket trading </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme rose more than 6% in premarket trading \n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-21 17:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(June 21)&nbsp;Orphazyme rose more than 6% in premarket trading.&nbsp;</p>\n<p><img src=\"https://static.tigerbbs.com/a1e2eb27cc68ce74ddd21a64a64634cf\" tg-width=\"719\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Orphazyme</b>, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last&nbsp;Friday.</p>\n<p><b>So what</b></p>\n<p>The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.</p>\n<p>Instead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.</p>\n<p>Many institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.</p>\n<p><b>Now what</b></p>\n<p>According to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.</p>\n<p>Some shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.</p>\n<p>Despite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.</p>\n<p></p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1184501396","content_text":"(June 21) Orphazyme rose more than 6% in premarket trading. \n\nWhat happened\nShares of Orphazyme, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last Friday.\nSo what\nThe FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.\nInstead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.\nMany institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.\nNow what\nAccording to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.\nSome shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.\nDespite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"tweetType":1,"viewCount":561,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":188515238,"gmtCreate":1623454701824,"gmtModify":1631891684004,"author":{"id":"3586338829912658","authorId":"3586338829912658","name":"Jordern5665","avatar":"https://static.tigerbbs.com/a1392e698d9d8446e6f5ac612e339304","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586338829912658","authorIdStr":"3586338829912658"},"themes":[],"htmlText":"[Cry]&nbsp;","listText":"[Cry]&nbsp;","text":"[Cry]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/188515238","repostId":"2142858202","repostType":4,"isVote":1,"tweetType":1,"viewCount":786,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":151241265,"gmtCreate":1625096396357,"gmtModify":1631891683958,"author":{"id":"3586338829912658","authorId":"3586338829912658","name":"Jordern5665","avatar":"https://static.tigerbbs.com/a1392e698d9d8446e6f5ac612e339304","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586338829912658","authorIdStr":"3586338829912658"},"themes":[],"htmlText":"Thanks&nbsp;","listText":"Thanks&nbsp;","text":"Thanks","images":[{"img":"https://static.tigerbbs.com/d1cbb1a770832b5037394f9ae1894e5d","width":"750","height":"1238"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/151241265","isVote":1,"tweetType":1,"viewCount":1317,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":128455071,"gmtCreate":1624528879993,"gmtModify":1631891683966,"author":{"id":"3586338829912658","authorId":"3586338829912658","name":"Jordern5665","avatar":"https://static.tigerbbs.com/a1392e698d9d8446e6f5ac612e339304","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586338829912658","authorIdStr":"3586338829912658"},"themes":[],"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128455071","repostId":"2145043969","repostType":4,"isVote":1,"tweetType":1,"viewCount":1321,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":183450283,"gmtCreate":1623343136942,"gmtModify":1631891684017,"author":{"id":"3586338829912658","authorId":"3586338829912658","name":"Jordern5665","avatar":"https://static.tigerbbs.com/a1392e698d9d8446e6f5ac612e339304","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586338829912658","authorIdStr":"3586338829912658"},"themes":[],"htmlText":"[Cool]&nbsp;","listText":"[Cool]&nbsp;","text":"[Cool]","images":[{"img":"https://static.tigerbbs.com/5ea4062b862709c77427ce72a351be07","width":"1125","height":"3199"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/183450283","isVote":1,"tweetType":1,"viewCount":1014,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}